In a newborn female presenting shortly after birth with erosive‑bullous lesions on the genital area, acral sites, and scalp, and whose mother has a known history of pemphigus vulgaris, what is the differential diagnosis, recommended diagnostic work‑up, and initial management?

Neonatal Pemphigus Vulgaris: Differential Diagnosis and Management

This neonate has neonatal pemphigus vulgaris (NPV) due to transplacental transfer of maternal anti-desmoglein 3 IgG autoantibodies, which is the most likely diagnosis given the maternal history and clinical presentation. 1

Primary Differential Diagnosis

The key differential diagnoses to consider in this clinical scenario include:

• Neonatal pemphigus vulgaris (NPV): Most likely diagnosis given maternal pemphigus vulgaris history and characteristic distribution (genital, acral, scalp). NPV occurs in approximately 45% of neonates born to mothers with active pemphigus due to passive transfer of maternal IgG autoantibodies across the placenta. 1

• Epidermolysis bullosa (EB): Must be excluded, particularly if lesions appeared at sites of trauma or friction. However, maternal history of pemphigus vulgaris makes NPV far more probable. 2

• Neonatal herpes simplex virus (HSV) infection: Consider if vesiculopustular lesions are present, particularly with systemic signs. Requires urgent viral culture and PCR testing. 2

• Bullous impetigo: Typically presents with flaccid bullae that rupture easily, leaving honey-colored crusts. Bacterial culture would be positive for Staphylococcus aureus. 2

• Neonatal gestational pemphigoid: Extremely rare (5-10% of maternal cases), but theoretically possible if mother had undiagnosed gestational pemphigoid. However, the maternal diagnosis is pemphigus vulgaris, not gestational pemphigoid. 3

Diagnostic Work-Up

Immediate diagnostic steps should include:

• Skin biopsy for histopathology: Look for suprabasilar acantholysis with tombstone appearance of basal keratinocytes, which is pathognomonic for pemphigus vulgaris. 4, 5

• Direct immunofluorescence (DIF) of perilesional skin: Will demonstrate intercellular IgG and C3 deposition in a "fishnet" or "chicken wire" pattern throughout the epidermis. 4, 6

• Indirect immunofluorescence (IIF) of neonatal serum: Will detect circulating anti-desmoglein 3 IgG autoantibodies, predominantly IgG4 subtype. 6, 5

• ELISA testing for anti-desmoglein antibodies: Quantify anti-Dsg3 and anti-Dsg1 antibodies. In NPV with mucocutaneous involvement, expect high anti-Dsg3 titers with low or absent anti-Dsg1 titers. 5

• Bacterial and viral cultures: Obtain swabs from erosions to exclude superinfection, particularly HSV and bacterial pathogens. 1

• Tzanck smear: May show acantholytic cells, though this is non-specific and less reliable than biopsy with immunofluorescence. 2

Initial Management

The prognosis for neonatal pemphigus vulgaris is excellent, with spontaneous resolution expected within 4 weeks as maternal antibodies are cleared from the neonatal circulation. 1

Wound Care and Infection Prevention

• Gentle blister management: Pierce blisters at the base with sterile needle (bevel up) to facilitate gravity drainage. Do not deroof blisters. Apply gentle pressure with sterile gauze to absorb fluid. 1

• Antimicrobial cleansing: Cleanse affected areas with antimicrobial solution before and after blister drainage. Daily washing with antibacterial products decreases colonization risk. 1

• Nonadherent dressings: Apply to drained blisters using aseptic technique. Change dressings with barrier nursing precautions for extensive erosions. 1

• Infection surveillance: Monitor closely for signs of local or systemic infection, as sepsis is a major cause of mortality in pemphigus. Send bacterial and viral swabs if clinical signs of infection develop. 1

Topical Therapy

• Mild topical corticosteroids: Apply to erosions to facilitate re-epithelialization. Most neonatal cases resolve spontaneously or with mild topical corticosteroids alone within 4 weeks. 1

• Avoid prolonged high-potency topical corticosteroids: Use only mild-to-moderate potency preparations in neonates to minimize systemic absorption and adverse effects. 7

Systemic Therapy (Rarely Needed)

• Systemic corticosteroids are rarely required for neonatal pemphigus, as the condition is self-limiting. However, if extensive mucocutaneous involvement causes feeding difficulties or significant morbidity, consider low-dose oral prednisolone (0.5-1 mg/kg/day). 1

• Pain management: Provide appropriate analgesia, particularly before dressing changes. Neonatal pain assessment and management should involve neonatology consultation. 1

Monitoring and Follow-Up

• Expected timeline: All lesions should resolve within 4 weeks as maternal IgG antibodies are metabolized and cleared from neonatal circulation. 1, 4

• Serial antibody titers: Consider monitoring anti-desmoglein antibody levels to confirm declining titers, though this is not routinely necessary if clinical improvement is evident. 6, 5

• Feeding assessment: Oral erosions may impair feeding. Involve lactation support or neonatology if oral intake is compromised. 1

• No long-term risk: Neonatal pemphigus vulgaris has never been reported to persist beyond the neonatal period or progress to childhood/adult disease. 3, 2

Common Pitfalls and Caveats

• Do not delay diagnosis: Early recognition prevents unnecessary invasive testing and inappropriate treatments. The maternal history of pemphigus vulgaris is the critical diagnostic clue. 1, 2

• Do not confuse with congenital infections: HSV and bacterial infections require urgent antimicrobial therapy, whereas NPV is self-limiting. Always obtain cultures to exclude infection. 1, 2

• Do not assume epidermolysis bullosa: EB would not resolve spontaneously within weeks and lacks maternal autoimmune history. Skin biopsy with immunofluorescence definitively distinguishes these conditions. 2

• Do not overtreate: Aggressive systemic immunosuppression is unnecessary and potentially harmful in neonates, as NPV resolves spontaneously. Reserve systemic therapy for severe cases with significant morbidity. 1

• Monitor for infection vigilantly: Infection and sepsis are the primary risks in neonatal pemphigus. Maintain strict aseptic technique with wound care and have a low threshold for systemic antibiotics if infection is suspected. 1

• Reassure parents about prognosis: Unlike maternal pemphigus vulgaris, neonatal disease is transient and does not indicate the infant will develop pemphigus later in life. 1, 2